| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
|
Medicine details |
|
| Medicine name | atezolizumab (Tecentriq®) |
| Formulation | 1200 mg concentrate for solution for infusion |
| Reference number | 2863 |
| Indication | Monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy. Patients with EGFR activating mutations or ALK-positive tumour mutations should also have received targeted therapy before receiving Tecentriq |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2017 |
| NICE guidance | |